文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

印度比哈尔邦内脏利什曼病病例漏报情况估计。

Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India.

机构信息

Division of Epidemiology and Biostatistics, Rajendra Memorial Research Institute of Medical Science, Indian Council of Medical Research, Patna, Bihar, India.

出版信息

Am J Trop Med Hyg. 2010 Jan;82(1):9-11. doi: 10.4269/ajtmh.2010.09-0235.


DOI:10.4269/ajtmh.2010.09-0235
PMID:20064987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2803501/
Abstract

We estimated the level of under-reporting of visceral leishmaniasis (VL) cases by comparing the actual reported cases with those expected as estimated using age- and sex-stratified incidence proportions obtained in a cohort of 31,324 persons. The average incidence proportion of VL cases in study population was 5.7/1,000 (95% confidence interval [CI] = 4.88-6.54) and 1.09/1,000 persons (95% CI = 0.99-1.20) based on the reported cases in two primary health centers. The overall magnitude of VL cases not reported to the government agencies was higher by a factor 4.17 (95% CI = 3.75-4.63) than for reported cases. The levels of under-reporting were 4.74 (95% CI = 4.11-5.47) in males and 3.51 (95% CI = 2.99-4.11) in females with no significant difference (P > 0.05). It was significantly higher in persons >or= 30 years of age than in persons 30 years of age (P < 0.05).

摘要

我们通过将实际报告的病例与使用 31324 人队列中获得的按年龄和性别分层的发病率比例估计的预期病例进行比较,估计了内脏利什曼病(VL)病例的漏报水平。研究人群中 VL 病例的平均发病率比例为 5.7/1000(95%置信区间[CI] = 4.88-6.54)和 1.09/1000 人(95%CI = 0.99-1.20)基于两个初级保健中心报告的病例。与报告病例相比,未向政府机构报告的 VL 病例总体规模高出 4.17 倍(95%CI = 3.75-4.63)。漏报率为男性 4.74(95%CI = 4.11-5.47),女性 3.51(95%CI = 2.99-4.11),无显著差异(P > 0.05)。年龄≥30 岁的人群明显高于 30 岁的人群(P < 0.05)。

相似文献

[1]
Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India.

Am J Trop Med Hyg. 2010-1

[2]
Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

Trop Med Int Health. 2006-6

[3]
Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India.

Am J Trop Med Hyg. 2010-9

[4]
Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India.

Trop Med Int Health. 2010-5-6

[5]
Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India.

BMC Infect Dis. 2015-2-6

[6]
Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008.

PLoS One. 2011-3-4

[7]
Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India.

Parasit Vectors. 2017-12-7

[8]
Low castes have poor access to visceral leishmaniasis treatment in Bihar, India.

Trop Med Int Health. 2012-3-5

[9]
Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Transmission at the Village Level in Bihar, India.

Front Cell Infect Microbiol. 2021

[10]
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India.

Am J Trop Med Hyg. 2009-3

引用本文的文献

[1]
The story of elimination of visceral leishmaniasis (kala-azar) in India-Challenges towards sustainment.

PLoS Negl Trop Dis. 2025-8-19

[2]
Leishmaniasis in Humans and Animals: A One Health Approach for Surveillance, Prevention and Control in a Changing World.

Trop Med Infect Dis. 2024-10-28

[3]
Arsenic exposure to mouse visceral leishmaniasis model through their drinking water linked to the disease exacerbation via modulation in host protective immunity: a preclinical study.

Sci Rep. 2023-12-5

[4]
Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review.

Trop Med Infect Dis. 2023-9-10

[5]
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.

PLoS Negl Trop Dis. 2022-6

[6]
Overcoming roadblocks in the development of vaccines for leishmaniasis.

Expert Rev Vaccines. 2021-11

[7]
Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.

PLoS Negl Trop Dis. 2021-8

[8]
Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India.

Front Cell Infect Microbiol. 2021

[9]
Optimizing Village-Level Targeting of Active Case Detection to Support Visceral Leishmaniasis Elimination in India.

Front Cell Infect Microbiol. 2021

[10]
Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era.

Front Cell Infect Microbiol. 2021

本文引用的文献

[1]
Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

Trop Med Int Health. 2006-6

[2]
Kala-azar--progress against a neglected disease.

N Engl J Med. 2002-11-28

[3]
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

Lancet Infect Dis. 2002-8

[4]
Socio-economics of visceral leishmaniasis in Bihar (India).

Trans R Soc Trop Med Hyg. 2000

[5]
Epidemiology of visceral leishmaniasis in India.

Natl Med J India. 1999

[6]
Leishmaniasis. Public health aspects and control.

Clin Dermatol. 1996

[7]
Changes in age incidence of kala-azar in India.

Indian J Public Health. 1995

[8]
An estimate of kala azar in 1991 in district Vaishali and Bihar.

J Commun Dis. 1994-6

[9]
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).

Trans R Soc Trop Med Hyg. 1984

[10]
Control of the leishmaniases. Report of a WHO Expert Committee.

World Health Organ Tech Rep Ser. 1990

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索